false 2022-11-22 0001532390 --03-31 The
Alkaline Water Company Inc. 0001532390 2022-11-22 2022-11-22
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest
event reported): November 22,
2022
THE ALKALINE WATER COMPANY INC.
(Exact name of registrant as specified in its charter)
Nevada |
001-38754 |
99-0367049 |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification
No.) |
8541 E. Anderson Drive, Suite 100
Scottsdale,
Arizona, United States 85255
(Address of principal
executive offices) (ZIP Code)
Registrant’s telephone number,
including area code: (480)
656-2423
Not
Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions:
☐ Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading Symbols |
|
Name
of each exchange on which registered |
Common stock, par value $0.001 per
share |
|
WTER |
|
The Nasdaq Stock Market
LLC |
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§ 240.12b -2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act. ☐
Item 3.02
Unregistered Sales of Equity Securities
On November 23, 2022, we entered
into private placement subscription agreements, whereby we issued
an aggregate of 1,100,000 shares of our Series E Preferred Stock
("Series E Preferred Stock") at a price of US$1.00 per share
of Series E Preferred Stock for gross proceeds of US$1,100,000.
Pursuant to the subscription agreements, in consideration for the
subscribers' execution and delivery of the subscription agreements,
we also issued an aggregate of 880,000 shares of our common stock
(the "Commitment Shares") at a deemed price of US$0.25 per
Commitment Share.
Holders of the Series E Preferred
Stock (the "Holders") are entitled to receive dividends at
the rate per share (as a percentage of the stated value per share)
of 6% per annum, payable on each anniversary date of the original
issue date of shares of Series E Preferred Stock held by applicable
Holders in a number of shares of our common stock per share of the
Series E Preferred Stock equal to the quotient obtained by dividing
the dollar amount of such dividend payment by applicable market
price. A stated value of each share of the Series E Preferred Stock
is US$1.00. Any accrued but unpaid dividends on the Series E
Preferred Stock being converted will be paid in our common stock
upon the conversion of the Series E Preferred Stock. If we pay a
dividend on our common stock while the shares of the Series E
Preferred Stock are outstanding, the Holders will be entitled to
receive a dividend per share of Series E Preferred Stock equal to
the dividend per share of our common stock. Such dividend will be
payable on the same terms and conditions as the payment of the
dividend on our common stock.
Each share of Series E Preferred
Stock will be convertible, at any time after the date that is
twelve months from the original issue date, at our option, into
that number of units (each, a "Unit") determined by dividing
the stated value of such share of Series E Preferred Stock by
US$0.25 (the "Conversion Price"). Each Unit will consist of
one share of our common stock and one-half of one common stock
purchase warrant with each whole common stock purchase warrant
entitling the holder thereof to acquire one additional share of our
common stock at an exercise price equal of 125% of the Conversion
Price for a period of three years following the conversion date. A
Holder may, at its option, at any time and from time to time after
January 31, 2023, convert all, but no less than all, of shares of
Series E Preferred Stock held by such Holder into that number of
Units determined by dividing the stated value of such shares of
Series E Preferred Stock by the Conversion Price. Each share of the
Series E Preferred Stock will automatically convert, upon the
occurrence of a Fundamental Transaction (as defined below), into
that number of Units determined by dividing the stated value of
such share of Series E Preferred Stock by the Conversion Price. The
conversion right is subject to the beneficial ownership limitation,
which will be 4.99% of the number of shares of our common stock
outstanding immediately after giving effect to the issuance of
shares of our common stock issuable upon conversion of the Series E
Preferred Stock held by the applicable Holder. The Holder may
increase or decrease the beneficial ownership limitation upon not
less than 61 days' prior notice to our company, but in no event
will such beneficial ownership exceed 9.99%.
Except with respect to a
Fundamental Transaction, as required by law, or as required by the
articles of incorporation of our company, the Holders and the
holders of our common stock will be entitled to notice of any
stockholders' meeting and to vote as a single class upon any matter
submitted to the stockholders for a vote, on the following basis:
(i) holders of our common stock will have one vote per share of our
common stock held by them; and (ii) holders of Series E Preferred
Stock will have one vote per share of Series E Preferred Stock held
by them. With respect to a Fundamental Transaction, the Holders
will be entitled to notice of any stockholders' meeting and to vote
as a separate class and will have one vote per share of Series E
Preferred Stock by them. A Fundamental Transaction means (i) any
merger or consolidation of our company with or into another entity
(but excluding a merger effected solely for the purpose of changing
the jurisdiction of the incorporation of our company or changing
the name of our company or liquidating, dissolving or winding-up
one or more subsidiaries of our company), (ii) any sale, lease,
license, assignment, transfer, conveyance or other disposition of
all or substantially all of our company's assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase
offer, tender offer or exchange offer (whether by our company or
another individual or entity) is completed pursuant to which
holders of our common stock are permitted to sell, tender or
exchange their shares for other securities, cash or property and
has been accepted by the holders of 50% or more of the outstanding
shares of our common stock, or (v) one or more related transactions
consummating a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with
another individual or entity or group of individuals or entities
whereby such other individual or entity or group acquires more than
50% of the outstanding shares of our common stock (not including
any shares of common stock held by the other individual or entity
making or party to, or associated or affiliated with the other
individual or entity making or party to, such stock or share
purchase agreement or other business combination).
The shares of the
Series E Preferred Stock cannot be redeemed.
Of the 1,100,000 shares of Series E
Preferred Stock and 880,000 Commitment Shares we issued: (i)
600,000 shares of Series E Preferred Stock and 480,000 Commitment
Shares were issued pursuant to the exemption from registration
under the Securities Act of 1933, as amended provided by Section
4(a)(2) and/or Rule 506 of Regulation D promulgated under the
Securities Act of 1933, as amended to two investors, each of whom
is an "accredited investor" within the meaning ascribed to that
term in Regulation D promulgated under the Securities Act of 1933,
as amended; and (ii) 500,000 shares of Series E Preferred Stock and
400,000 Commitment Shares were issued to one non-U.S. person (as
that term is defined in Regulation S of the Securities Act of 1933,
as amended) in an offshore transaction relying on Regulation S
and/or Section 4(a)(2) of the Securities Act of 1933, as
amended.
Disclosure Required by MI
61-101
David Rauch, a director of our
company, participated in the private placement and subscribed for
100,000 Series E Preferred Stock and was issued 80,000 Commitment
Shares, which constituted a "related party transaction" within the
meaning of Multilateral Instrument 61-101 Protection of Minority
Security Holders in Special Transactions ("MI
61-101").
The following supplementary
information is provided in accordance with Section 5.2 of MI
61‐101.
(a) a description of the
transaction and its material terms:
We entered into a subscription
agreement with Mr. Rauch, whereby he agreed to purchase 100,000
Series E Preferred Stock at a price of US$1.00 per Series E
Preferred Stock for proceeds of US$100,000. Pursuant to the
subscription agreement, in consideration for Mr. Rauch's execution
and delivery of the subscription agreement, we also issued to Mr.
Rauch 80,000 Commitment Shares at a deemed price of US$0.25 per
Commitment Share.
(b) the purpose and business
reasons for the transaction:
Proceeds of the private placement
are expected to be used for working capital and general corporate
purposes.
(c) the
anticipated effect of the transaction on the issuer's business and
affairs:
See item (b).
(d) a description of:
(i) the interest in the
transaction of every interested party and of the related parties
and associated entities of the interested parties:
See item (a).
(ii) the anticipated effect of
the transaction on the percentage of securities of the issuer, or
of an affiliated entity of the issuer, beneficially owned or
controlled by each person or company referred to in subparagraph
(i) for which there would be a material change in that
percentage:
The following table sets out the
effect of the private placement (the "Offering") on the
percentage of securities of our company beneficially owned or
controlled by Mr. Rauch:
Name and
Position |
Dollar
Amount of
Shares
Purchased |
Number of
Shares
Purchased |
No. of
Shares Held
prior to
Closing of
the Offering |
Percentage of
Issued and
Outstanding
Shares prior to
Closing of the
Offering |
No. of Shares
Held After
Closing of
the Offering |
Percentage of
Issued and
Outstanding
Shares After
Closing of
the Offering |
David Rauch
Director |
US$100,000 |
100,000 shares of Series E Preferred Stock and 80,000 Commitment
Shares |
Undiluted and Diluted:
0 |
Undiluted and Diluted:
0% |
Undiluted and Diluted:
80,000 |
Undiluted and Diluted:
*(1) |
*Less
than one percent
(1) Based on
147,930,459 shares of common stock outstanding after the completion
of the Offering.
(e) unless
this information will be included in another disclosure document
for the transaction, a discussion of the review and approval
process adopted by the board of directors and the special
committee, if any, of the issuer for the transaction, including a
discussion of any materially contrary view or abstention by a
director and any material disagreement between the board and the
special committee:
Mr. Rauch
abstained on the resolution of the board of directors approving the
Offering with respect to his subscription. A special committee was
not established in connection with the approval of the Offering,
and no materially contrary view or abstention was expressed or made
by any director.
(f) a summary
in accordance with section 6.5 of MI 61‐101, of the formal
valuation, if any, obtained for the transaction, unless the formal
valuation is included in its entirety in the material change report
or will be included in its entirety in another disclosure document
for the transaction:
Not
applicable.
(g)
disclosure, in accordance with section 6.8 of MI 61‐101, of every
prior valuation in respect of the issuer that related to the
subject matter of or is otherwise relevant to the
transaction:
(i) that has
been made in the 24 months before the date of the material change
report:
Not
applicable.
(ii) the
existence of which is known, after reasonable enquiry, to the
issuer or to any director or officer of the issuer:
Not
applicable.
(h) the
general nature and material terms of any agreement entered into by
the issuer, or a related party of the issuer, with an interested
party or a joint actor with an interested party, in connection with
the transaction:
See item
(a).
(i)
disclosure of the formal valuation and minority approval
exemptions, if any, on which the issuer is relying under sections
5.5 and 5.7 of MI 61‐101 respectively, and the facts supporting
reliance on the exemptions:
The issuance of
100,000 shares of Series E Preferred Stock and 80,000 Commitment
Shares to Mr. Rauch was exempt from the valuation requirement of MI
61-101 by virtue of the exemptions contained in Section 5.5(a) of
MI 61-101 in that the fair market value of the shares subscribed by
Mr. Rauch did not exceed 25% of our company's market capitalization
and from the minority shareholder approval requirements of MI
61-101 by virtue of the exemption contained in section 5.7(a) of MI
61-101 in that the fair market value of the shares subscribed by
Mr. Rauch did not exceed 25% of our company's market
capitalization.
As this current
report on Form 8-K is being filed less than 21 days before the
closing of the Offering, there is a requirement under MI 61-101 to
explain why the shorter period was reasonable or necessary in the
circumstances. In the view of our company, it was necessary to
immediately close the Offering and therefore, such shorter period
was reasonable and necessary in the circumstances to improve our
company's financial position.
Item 3.03 Material Modifications
to Rights of Security Holders.
The information contained in Items
3.02 and 5.03 of this current report on Form 8-K is responsive to
this item.
Item 5.03 Amendments to Articles
of Incorporation or Bylaws; Change in Fiscal Year.
On November 22, 2022, we designated
2,000,000 shares of the authorized and unissued preferred stock of
our company as "Series E Preferred Stock" by filing a Certificate
of Designation with the Secretary of State of the State of Nevada.
For a description of Series E Preferred Stock, please see Item 3.02
of this current report on Form 8-K.
Item 7.01 Regulation FD
Disclosure.
A copy of our news release dated
November 23, 2022 is being furnished herewith as Exhibit 99.1.
In accordance with General
Instruction B.2 of Form 8-K, the information in Item 7.01 of this
current report on Form 8-K, including Exhibit 99.1, is being
furnished and shall not be deemed to be "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act"), or otherwise subject to the liabilities of that section,
and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933
or the Exchange Act, except as shall be expressly set forth by
specific reference in such filing.
Item
9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
THE ALKALINE WATER COMPANY
INC.
/s/ David A. Guarino
David
A. Guarino
Chief Financial
Officer and Director
November 23, 2022